News

[pdf-embedder url="https://www.spera-pharma.co.jp/wp-content/uploads/2022/09/220916_news_Notice-of-Change-of-Board-Members.pdf" title="220916_news_Notice of Change of Board Members"]

Osaka (Japan), February 16, 2022 – Interprotein Corporation and SPERA PHARMA, Inc. today hereby announce that we have signed an agreement for comprehensive collaboration aiming at research & development, m...

A paper by Masatoshi Yamada and others of the Pharmaceutical Research Division has been published in the academic journal "Organic Process Research & Development" of the American Chemical Society. 【Det...

In recent years, there have been cases where new compounds with extremely complicated chemical structures and compounds with unknown physical properties have been identified as new drug candidates, and SPERA P...

A paper by Masatoshi Yamada and others of the Pharmaceutical Research Division has been published in the academic journal "Organic Process Research & Development" of the American Chemical Society. 【Det...

A paper by Masatoshi Yamada and others of the Pharmaceutical Research Division has been published in the academic journal "Organic Process Research & Development" of the American Chemical Society. 【Det...

The following monthly magazine, in which our researcher participated in writing, has been published. Book: PHARM STAGE Monthly, December 2019 Publication date: December 27, 2019 Theme: [Special Feature] M...

The following books, in which our researchers participated in writing, have been published.。   Book: Procedures for Implementing Technology Transfer (Test Method, Manufacturing Process) and Ensurin...

Two papers by our researchers (research at Takeda Pharmaceutical Sciences) were featured in the August issue of Synfacts, a professional journal that selects and introduces outstanding research from among the ...

Two of our researchers from Chemical R&D Division presented at the ACS National Meeting held in San Diego, USA, August 25-29, 2019. Our technologies and experiences in API process research and developme...

SPERA PHARMA had a booth at the International Symposium on Process Chemistry held at the Kyoto International Conference Center for three days from Wednesday, July 24 to Friday, July 26, 2019. Thank you very mu...

SPERA PHARMA had a booth at the 1st PharmaLab Expo , which was held at Tokyo Big Sight Aomi Exhibition Hall for three days from Wednesday, July 3 to Friday, July 5, 2019. Thank you very much for stopping by o...

　Akira Horinouchi（Director , Legal Affairs and Facility Management Department), who is in charge of PDE and exposure control level setting in our company, co-authored a paper on PDE setting as follows. Titl...

Kishi Kasei Co., Ltd. (President: Daisuke Maezawa) and SPERA PHARMA, Inc. (President: Toshio Yoshioka) have agreed to a business collaboration combining Kishi Kasei’s contract manufacturing of Biomaterials and...

At the 4th International Symposium for Medicinal Sciences held on March 27, at Kanazawa Art Hall/Kanazawa Motenashi Dome during the 138th Annual Meeting of The Pharmaceutical Society of Japan (March 25 - 28), ...

At The 12th Process Chemistry Lounge, held at the Yugawara Traning Center of Wako Pure Chemical Industries, Ltd., on December 1 - 2, 2017, Kazuki Azuma of Chemical R&D Division gave a lecture on "Development o...

At the 2017 Winter Symposium of the Japanese Society of Process Chemistry held in Nagasaki city on December 8, 2017, the JSPC Award Ceremony was held for the awardees selected at the 2017 Summer Symposium. Say...

An article on API process research in the Chemical R&D Division of the company has been published and is described by one of the authors, Dr. Ikemoto. http://pubs.acs.org/doi/10.1021/acs.oprd.7b00313 Title: ...

SPERA PHARMA exhibited a company's booth at The 38th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, which was held for three days from December 7, 2017 at PACIFIC...

SPERA PHARMA made a debut exhibit at CPhI worldwide 2017, which was held for three days from October 24, 2017 in Frankfurt, Germany. Details of the SPERA PHARMA business model and technologies were actively pr...

A researcher in the Chemical R&D Division of SPERA PHARMA, Osamu Yabe, gave a poster presentation (2P-076) at The 35th Medicinal Chemistry Symposium, which was held on October 25∼27 in the Toyota Lecture Hall ...

SPERA PHARMA exhibited a company's booth at The 35th Medicinal Chemistry Symposium held at Nagoya University (October 25∼26). Many attendees from pharmaceutical companies, venture companies and academia visit...

Chirality 2017; 29th International Symposium on Chiral Discrimination (ISCD-29）was held at Waseda University International Conference Center on July 9-12. This international symposium emphasizes chirality as...

The 21st Workshop on Pharmaceutical Technology Succession was held by the Academy of Pharmaceutical Science and Technology, Japan (APSTJ) at Dome-mae campus of Meijo University on Friday, July 14, 2017, and Mr...

Recently, health authorities pay attention to residual impurities in drug substances and drug products, and require pharmaceutical companies to control them strictly. Especially, the inquiries on PMIs control...

The article on API process research described by Misayo Sera and Hideya Mizufune in SPERA PHARMA was published in Tetrahedron. (Integrated Pd-catalyzed cross-coupling strategies for furnishing α-carbolines, T...

Researchers, Sayuri Hirano and Kazushi Hosoi of Chemical R&D Division gave the two poster presentations at 2017 Summer Symposium of The Japanese Society for Process Chemistry (JSPC) held on August 3 - 4 at Osa...

One of the characteristic technologies that SPERA PHARMA took over from Takeda Pharmaceutical Company is chiral technology developed over many years in the Process Chemistry Division. All equipment and researc...

At Interphex 2017, held from June 28 at the Tokyo Big Sight, SPERA PHARMA, a newly launched member of the Bushu Pharmaceuticals Group, exhibited its services for the first time. Despite the short notice, more ...

Under a strategic partnership with Takeda Pharmaceutical Company, the Bushu Pharmaceuticals Group began conducting business on July 1, 2017, after a group of specialized CMC researchers and technicians at Take...